Intermediate Strengths and Inflated Prices: The Story of Transdermal Fentanyl Patches.
J Palliat Med
; 25(9): 1335-1337, 2022 09.
Article
em En
| MEDLINE
| ID: mdl-35763285
ABSTRACT
In 2015, Mylan pharmaceuticals received final approval from the Food and Drug Administration for its Supplemental Abbreviated New Drug Application and introduced three new intermediate strengths of transdermal fentanyl patches to the U.S. drug market.1 With this approval, Mylan added 37.5 , 62.5, and 87.5 mcg/hr strength patches to existing 12, 25, 50, 75, and 100 mcg/hr strength patches. Today, these intermediate strength patches cost many times more than older strengths. In this commentary, we discuss the clinical implications of intermediate strengths of the fentanyl patch, explore mechanisms for price differences, and offer practice-based and policy solutions to address these differences.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Fentanila
/
Analgésicos Opioides
Tipo de estudo:
Health_economic_evaluation
Limite:
Humans
Idioma:
En
Revista:
J Palliat Med
Assunto da revista:
SERVICOS DE SAUDE
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Estados Unidos